Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 840-845

  Rastogi, Maynika V ^a   Stork, Linda ^b   Druker, Brian ^c   Blasdel, Carolyn ^c   Nguyen, Thuan ^b   Boston, Bruce A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Children; Growth; Tyrosine kinase inhibitors

Indexed keywords

GROWTH FACTOR; IMATINIB; INSULIN LIKE BINDING PROTEIN 3; SOMATOMEDIN C; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ANAPHYLACTOID PURPURA; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE AGE; CHILD; CHILD GROWTH; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FREE THYROXINE INDEX; GROWTH DISORDER; HIP DISLOCATION; HOSPITALIZATION; HUMAN; HUMERUS FRACTURE; LABORATORY TEST; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THYROID GLAND; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BODY HEIGHT; BODY MASS INDEX; CHILD; FEMALE; GROWTH DISORDERS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; THYROID HORMONES; TIME FACTORS;

EID: 84866167173     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24121     Document Type: Article

References (28)

1. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 31-36.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
3. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
4. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2004; 104: 2655-2660.
5. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006; 20: 187-192.
6. Vandyke K, Fitter S, Dewar AL, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010; 115: 766-774.
7. O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94: 1131-1136.
8. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
9. Hobernicht SL, Schweiger B, Zeitler P, et al. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer 2011; 56: 671-673.
10. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89: 251-252.
11. Mariani S, Giona F, Basciani S, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008; 372: 111-112.
12. Barr RD. Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer 2010; 55: 18-25.
13. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159: 676-681.
14. Meinolf S, Boehme J, Vaitl J, et al. Side Effects on the Heart and Skeleton of Growing Mice Attributed to Chronic Imatinib Exposure. 50th annual American society of hematology meeting 2008 (Abstract).
15. Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009; 23: 2155-2159.
16. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: Methods and development. National Center for Health Statistics. Vital Health Stat 2002; 11: 15.
17. Schmid H, Jaeger BA, Lohse J, et al. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009; DOI: 10.3324(haematol.2009.008359).
18. Kebapcilar L, Bilgir O, Alacacioglu I, et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Principles Pract 2009; 18: 360-363.
19. Brooks AJ, Waters MJ. The growth hormone receptor: Mechanism of activation and clinical implications. Nat Rev Endocrinol 2010; 6: 515-525.
20. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, et al. Defects in growth hormone receptor signalling. Trends Endocrinol Metab 2007; 18: 134-141.
21. Butler AA, Yakar S, Gewolb IH, et al. Insulin-like growth factor-I receptor signal transduction: At the interface between physiology and cell biology. Comp Biochem Physiol Part B Biochem Mol Biol 1998; 121: 19-26.
22. Lakshmikuttyamma A, Pastural E, Takahashi N, et al. Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 2008; 27: 3831-3844.
23. Ciarmatori S, Kiepe D, Haarmann A, et al. Signaling mechanisms leading to regulation of proliferation and differentiation of the mesenchymal chondrogenic cell line RCJ3.1C5.18 in response to IGF-I. J Mol Endocrinol 2007; 38: 493-508.
24. Kieswetter K, Schwartz Z, Alderete M, et al. Platelet derived growth factor stimulates chondrocyte proliferation but prevents endochondral maturation. Endocrine 1997; 6: 257-264.
25. Lupu F, Terwilliger JD, Lee K, et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
26. Vandyke K, Fitter S, Zannettino ACW. Letter to the editor:The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J 2011; 1: e2: DOI: 10.1038/bcj.2011.
27. Juul A. The role of Insulin-Like Growth Factors in Growth Hormone Deficiency. In: Ranke M, Price D, Reiter E, editors. Growth Hormone Therapy in Pediatrics-20 Years of KIGS. Basel: Karger 2007. p 70-82.
28. Frank GR. Constitutional delay of growth and puberty. Endocrinologist 2003; 13: 341-346.